Evidence map›Paper›PMID 37645789›Full record

ArticleResearch square2023

Identifying 1q amplification and PHF19 expressing high-risk cells associated with relapsed/refractory multiple myeloma.

Travis S Johnson, Parvathi Sudha, Enze Liu, Patrick Blaney, Gareth Morgan, Vivek S Chopra, Cedric Dos Santos, Michael Nixon, Kun Huang, Attaya Suvannasankha and 3 more

Open access · greenAbstract readPreprint
PubMed Full text at PMC Publisher
In one paragraph

Article in Research square, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 0 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

13 authors at 4 institutions in 2 countries.

Travis S JohnsonDepartment of Biostatistics and Health Data Science, School of Medicine, Indiana University, Indianapolis, IN, USA.ORCID 0000-0002-4628-2256
Parvathi SudhaMelvin and Bren Simon Comprehensive Cancer Center, Division of Hematology and Oncology, School of Medicine, Indiana University, Indianapolis, IN, USA.
Enze LiuMelvin and Bren Simon Comprehensive Cancer Center, Division of Hematology and Oncology, School of Medicine, Indiana University, Indianapolis, IN, USA.
Patrick BlaneyPerlmutter Cancer Center, Langone Health, New York University, New York, NY, USA.ORCID 0000-0002-9319-8866
Gareth MorganPerlmutter Cancer Center, Langone Health, New York University, New York, NY, USA.ORCID 0000-0002-4271-6360
Vivek S ChopraGenentech Inc., South San Francisco, CA, USA.
Cedric Dos SantosGenentech Inc., South San Francisco, CA, USA.
Michael NixonRoche Inc., Indianapolis, IN, USA.
Kun HuangDepartment of Biostatistics and Health Data Science, School of Medicine, Indiana University, Indianapolis, IN, USA.ORCID 0000-0002-8530-370X
Attaya SuvannasankhaMelvin and Bren Simon Comprehensive Cancer Center, Division of Hematology and Oncology, School of Medicine, Indiana University, Indianapolis, IN, USA.ORCID 0000-0001-9445-8781
Mohammad Abu ZaidMelvin and Bren Simon Comprehensive Cancer Center, Division of Hematology and Oncology, School of Medicine, Indiana University, Indianapolis, IN, USA.ORCID 0000-0002-4018-6941
Rafat AbonourMelvin and Bren Simon Comprehensive Cancer Center, Division of Hematology and Oncology, School of Medicine, Indiana University, Indianapolis, IN, USA.
Brian A WalkerCenter for Computational Biology and Bioinformatics, School of Medicine, Indiana University, Indianapolis, IN, USA.ORCID 0000-0002-8615-6254
Indiana University Health · USNYU Langone Health · USRoche (Sweden) · SEUniversity School · US

Funding

A deep-transfer-learning framework to transfer clinical information to single cells and spatial locations in cancer tissuesR21CA264339 · NCI · INDIANA UNIVERSITY INDIANAPOLIS · PI JOHNSON, TRAVIS STEELE, ZHANG, JIE · 2022 to 2023
$394k
NCI NIH HHS R21 CA264339
6 · The paper itself

Abstract

Multiple Myeloma is an incurable plasma cell malignancy with a poor survival rate that is usually treated with immunomodulatory drugs (iMiDs) and proteosome inhibitors (PIs). The malignant plasma cells quickly become resistant to these agents causing relapse and uncontrolled growth of resistant clones. From whole genome sequencing (WGS) and RNA sequencing (RNA-seq) studies, different high-risk translocation, copy number, mutational, and transcriptional markers have been identified. One of these markers,

Identifiers

PMID37645789
PMCPMC10462227
OpenAlexW4385891592

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.